IL6 and colitis: IA-0130 effectively inhibited the pathogenesis of colitis by modulating pro-inflammatory cytokine expression, protecting the intestinal epithelial barrier function to maintain intestinal barrier permeability, and inhibiting the hyperactivation of the IL-6 signaling pathway in DSS-induced mouse colitis.